The aim of the PEPPI (placental growth factor in prediction of placental insufficiency) study is to improve early identification of women at risk of preeclampsia. About 2-5% of all pregnant women develop preeclampsia and it is one of the most significant causes of morbidity and mortality among pregnant women and unborn children worldwide, thus being a significant cause of healthcare costs. The PEPPI study uses risk calculation program that is estimated to improve the identification of preeclampsia risk from current 40% to 60%. Efficient screening is important as aspirin treatment significantly reduces the risk of developing preeclampsia. 3000 mother-child-father trios will be recruited into the study in Oulu region. The research material includes blood tests, surveys, doctor's examinations and ultrasound examinations. More information: www.peppitutkimus.fi.

2025

2029